The DOI matches its Crossref record; 50 of the 51 references it cites were found in a registry or an index.
Successful use of fenfluramine as an add‐on treatment for Dravet syndrome
Open accessAbstract
Summary: Purpose: Despite the development of new antiepileptic drugs, Dravet syndrome frequently remains therapy resistant and is a catastrophic epilepsy syndrome. Fenfluramine is an amphetamine‐like drug that has been used in the past as a part of antiobesity treatments. Because of the possible cardiac adverse effects (valve thickening, pulmonary hypertension) associated with use of fenfluramine, it was withdrawn from the market in 2001. In Belgium, a Royal Decree permitted examination of the potential anticonvulsive effects of fenfluramine in a clinical trial consisting of a small group of patients diagnosed with Dravet syndrome. Methods: Herein, we report 12 patients, 7 female and 5 male, with a genetically proven (11 of 12) diagnosis of Dravet syndrome who received fenfluramine as add‐on therapy. Key Findings: Their ages at their last evaluation ranged from 3–35 years. The mean dosage of fenfluramine was 0.34 (0.12–0.90) mg/kg/day. Exposure duration to fenfluramine ranged from 1–19 years. Seven of the patients who were still receiving the fenfluramine treatment at the time of the last visit had been seizure‐free for at least 1 year. In total, patients had been seizure‐free for a mean of 6 (1–19) years. In seven patients, the fenfluramine treatment was interrupted once during the follow‐up; seizures reappeared in three of the seizure‐free patients. Subsequent reintroduction of fenfluramine controlled the seizures in these three patients again. Only two patients exhibited a mild thickening of one or two cardiac valves without clinical significance. Significance: Compared with a recent long‐term follow‐up series in which a maximum of 16% of patients with Dravet syndrome were seizure‐free, our result of 70% of patients with Dravet syndrome remaining seizure‐free is noteworthy. Given the limitations of this observational study, a larger prospective study should be undertaken to confirm these promising results.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Identification of the efficacy of fenfluramine in Dravet syndrome followed the observation that it was particularly beneficial in children with drug-resistant, self-induced photosensitive epilepsy 195 , resulting in seizure freedom in 7 of 12 patients with Dravet syndrome in one study 196 .”
From Developmental and epileptic encephalopathies (2024) · cites this paper as [196]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Proposal for Revised Clinical and Electroencephalographic Classification of Epileptic Seizures
(1981) · Epilepsia · doi:10.1111/j.1528-1157.1981.tb06159.x · Cited by 3,433
De Novo Mutations in the Sodium-Channel Gene SCN1A Cause Severe Myoclonic Epilepsy of Infancy
Claes, L., Del-Favero, J., Ceulemans, B., Lagae, L., Van Broeckhoven, C., & De Jonghe, P. (2001) · The American Journal of Human Genetics · doi:10.1086/320609 · Cited by 1,292
Self-citationEpileptic Syndromes in Infancy, Childhood and Adolescence
Stephenson, J. B. P. (2004) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2004.03.001 · Cited by 685
The core Dravet syndrome phenotype
Dravet, C. (2011) · Epilepsia · doi:10.1111/j.1528-1167.2011.02994.x · Cited by 630
Chiron, C., Marchand, M., Tran, A., Rey, E., d'Athis, P., Vincent, J., Dulac, O., & Pons, G. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03157-3 · Cited by 568
The spectrum of SCN1A-related infantile epileptic encephalopathies
Harkin, L. A., McMahon, J. M., Iona, X., Dibbens, L. M., Pelekanos, J. T., Zuberi, S. M., Sadleir, L. G., Andermann, E., Gill, D. S., Farrell, K., et al. (2007) · Brain · doi:10.1093/brain/awm002 · Cited by 530
The genetics of Dravet syndrome
Marini, C., Scheffer, I. E., Nabbout, R., Suls, A., Jonghe, P. D., Zara, F., & Guerrini, R. (2011) · Epilepsia · doi:10.1111/j.1528-1167.2011.02997.x · Cited by 276
Dravet syndrome: The long‐term outcome
Genton, P., Velizarova, R., & Dravet, C. (2011) · Epilepsia · doi:10.1111/j.1528-1167.2011.03001.x · Cited by 266
LES EPILEPSIES GRAVES DE L'ENFANT.
Dravet, C. (1978) · Cited by 240
A long‐term follow‐up study of Dravet syndrome up to adulthood
Akiyama, M., Kobayashi, K., Yoshinaga, H., & Ohtsuka, Y. (2010) · Epilepsia · doi:10.1111/j.1528-1167.2009.02466.x · Cited by 192
Cited by
Sorted by citations
Molecular Targets of Cannabidiol in Neurological Disorders
Bih, C. I., Chen, T., Nunn, A. V. W., Bazelot, M., Dallas, M. L., & Whalley, B. J. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0377-3 · Cited by 602
Symonds, J. D., Zuberi, S. M., Stewart, K., McLellan, A., O‘Regan, M., MacLeod, S., Jollands, A., Joss, S., Kirkpatrick, M., Brunklaus, A., et al. (2019) · Brain · doi:10.1093/brain/awz195 · Cited by 459
Lagae, L., Sullivan, J., Knupp, K., Laux, L., Polster, T., Nikanorova, M., Devinsky, O., Cross, J. H., Guerrini, R., Talwar, D., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32500-0 · Cited by 384
Self-citationThe Pharmacoresistant Epilepsy: An Overview on Existent and New Emerging Therapies
Fattorusso, A., Matricardi, S., Mencaroni, E., Dell’Isola, G. B., Cara, G. D., Striano, P., & Verrottı, A. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.674483 · Cited by 287
Nabbout, R., Mistry, A., Zuberi, S., Villeneuve, N., Gil-Nagel, A., Sanchez-Carpintero, R., Stephani, U., Laux, L., Wirrell, E., Knupp, K., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2019.4113 · Cited by 251
Pharmacology of cannabinoids in the treatment of epilepsy
Gaston, T. E., & Friedman, D. J. (2017) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2016.11.016 · Cited by 222
Developmental and epileptic encephalopathies: from genetic heterogeneity to phenotypic continuum
Guerrini, R., Conti, V., Mantegazza, M., Balestrini, S., Galanopoulou, A. S., & Benfenati, F. (2023) · Physiological Reviews · doi:10.1152/physrev.00063.2021 · Cited by 196
Drug development for refractory epilepsy: The past 25 years and beyond
Golyala, A., & Kwan, P. (2016) · Seizure · doi:10.1016/j.seizure.2016.11.022 · Cited by 188
Scheffer, I. E., & Liao, J. (2020) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2019.12.023 · Cited by 180
Zebrafish Models of Neurodevelopmental Disorders: Past, Present, and Future
Sakai, C., Ijaz, S., & Hoffman, E. J. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00294 · Cited by 172
Balestrini, S., & Sisodiya, S. M. (2017) · Neuroscience Letters · doi:10.1016/j.neulet.2017.01.014 · Cited by 158
Large-Scale Phenotype-Based Antiepileptic Drug Screening in a Zebrafish Model of Dravet Syndrome
Dinday, M. T., & Baraban, S. C. (2015) · eNeuro · doi:10.1523/eneuro.0068-15.2015 · Cited by 157
Pharmacological Analysis of the Anti-epileptic Mechanisms of Fenfluramine in scn1a Mutant Zebrafish
Sourbron, J., Smolders, I. J., de Witte, P. A. M., & Lagae, L. G. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00191 · Cited by 142
Self-citationDevelopmental and epileptic encephalopathies
Scheffer, I. E., Zuberi, S., Mefford, H. C., Guerrini, R., & McTague, A. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00546-6 · Cited by 158
Fine, A. L., & Wirrell, E. C. (2020) · Pediatrics in Review · doi:10.1542/pir.2019-0134 · Cited by 146
The Pharmacological Basis of Cannabis Therapy for Epilepsy
Reddy, D. S., & Golub, V. M. (2016) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.230151 · Cited by 128
Wirrell, E. C. (2016) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/cjn.2016.249 · Cited by 115
Five‐year extended follow‐up status of 10 patients with Dravet syndrome treated with fenfluramine
Ceulemans, B., Schoonjans, A., Marchau, F., Paelinck, B. P., & Lagae, L. G. (2016) · Epilepsia · doi:10.1111/epi.13407 · Cited by 114
Self-citationA Practical Guide to the Treatment of Dravet Syndrome with Anti-Seizure Medication
Strzelczyk, A., & Schubert‐Bast, S. (2022) · CNS Drugs · doi:10.1007/s40263-022-00898-1 · Cited by 122
Zhang, Y., Kecskés, A., Copmans, D., Langlois, M., Crawford, A. D., Ceulemans, B., Lagae, L. G., de Witte, P. A. M., & Esguerra, C. V. (2015) · PLoS ONE · doi:10.1371/journal.pone.0125898 · Cited by 112
Self-citationBialer, M., Johannessen, S. I., Levy, R. H., Perucca, E., Tomson, T., & White, H. S. (2017) · Epilepsia · doi:10.1111/epi.13634 · Cited by 110
Seizing the moment: Zebrafish epilepsy models
Gaweł, K., Langlois, M., Martins, T., van der Ent, W., Tiraboschi, E., Jacmin, M., Crawford, A. D., & Esguerra, C. V. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.06.010 · Cited by 114
Stiripentol in D ravet syndrome: Results of a retrospective U . S . study
Wirrell, E. C., Laux, L., Franz, D. N., Sullivan, J. E., Saneto, R. P., Morse, R. P., Devinsky, O., Chugani, H. T., Hernandez, A. W., Hamiwka, L. D., et al. (2013) · Epilepsia · doi:10.1111/epi.12303 · Cited by 109
Monogenic Epilepsies: Disease Mechanisms, Clinical Phenotypes, and Targeted Therapies
Guerrini, R., Balestrini, S., Wirrell, E. C., & Walker, M. C. (2021) · Neurology · doi:10.1212/wnl.0000000000012744 · Cited by 108
Serotonergic Modulation as Effective Treatment for Dravet Syndrome in a Zebrafish Mutant Model
Sourbron, J., Schneider, H., Kecskés, A., Liu, Y., Buening, E., Lagae, L. G., Smolders, I. J., & de Witte, P. A. M. (2016) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5b00342 · Cited by 113
Self-citationDravet syndrome: Treatment options and management of prolonged seizures
Cross, J. H., Caraballo, R. H., Nabbout, R., Vigevano, F., Guerrini, R., & Lagae, L. G. (2019) · Epilepsia · doi:10.1111/epi.16334 · Cited by 117
Self-citationSchoonjans, A., Paelinck, B. P., Marchau, F., Gunning, B. W., Gammaitoni, A. R., Galer, B. S., Lagae, L. G., & Ceulemans, B. (2016) · European Journal of Neurology · doi:10.1111/ene.13195 · Cited by 104
Self-citationPreclinical Animal Models for Dravet Syndrome: Seizure Phenotypes, Comorbidities and Drug Screening
Griffin, A., Hamling, K. R., Hong, S., Anvar, M., Lee, L. P., & Baraban, S. C. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00573 · Cited by 103
Cannabidiol Therapy for Refractory Epilepsy and Seizure Disorders
Golub, V. M., & Reddy, D. S. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-57369-0_7 · Cited by 106
Guidance on Dravet syndrome from infant to adult care: Road map for treatment planning in Europe
Cardenal‐Muñoz, E., Auvin, S., Villanueva, V., Cross, J. H., Zuberi, S. M., Lagae, L. G., & Aibar, J. Á. (2021) · Epilepsia Open · doi:10.1002/epi4.12569 · Cited by 98
Self-citationSerotonin and sudden unexpected death in epilepsy
Petrucci, A. N., Joyal, K. G., Purnell, B. S., & Buchanan, G. F. (2019) · Experimental Neurology · doi:10.1016/j.expneurol.2019.113145 · Cited by 93
Recent Advances in the Drug Treatment of Dravet Syndrome
Wirrell, E. C., & Nabbout, R. (2019) · CNS Drugs · doi:10.1007/s40263-019-00666-8 · Cited by 92
Rodríguez-Muñoz, M., Sánchez‐Blázquez, P., Merlos, M., & Garzón-Niño, J. (2016) · Oncotarget · doi:10.18632/oncotarget.10095 · Cited by 87
Impact of fenfluramine on the expected SUDEP mortality rates in patients with Dravet syndrome
Cross, J. H., Galer, B. S., Gil‐Nagel, A., Devinsky, O., Ceulemans, B., Lagae, L. G., Schoonjans, A., Donner, E. J., Wirrell, E. C., Kothare, S. V., et al. (2021) · Seizure · doi:10.1016/j.seizure.2021.10.024 · Cited by 87
Self-citationLow-dose fenfluramine in the treatment of neurologic disorders: experience in Dravet syndrome
Schoonjans, A., Lagae, L. G., & Ceulemans, B. (2015) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285615607726 · Cited by 82
Self-citationZebrafish as Toxicological model for screening and recapitulate human diseases
Caballero, M. V., & Candiracci, M. (2018) · Journal of Unexplored Medical Data · doi:10.20517/2572-8180.2017.15 · Cited by 92
Reddy, D. S. (2022) · Experimental Neurology · doi:10.1016/j.expneurol.2022.114237 · Cited by 102
Pharmacotherapy for Dravet Syndrome
Wallace, A. D., Wirrell, E. C., & Kenney‐Jung, D. L. (2016) · Pediatric Drugs · doi:10.1007/s40272-016-0171-7 · Cited by 79
The pharmacological management of Lennox-Gastaut syndrome and critical literature review
Verrottı, A., Striano, P., Iapadre, G., Zagaroli, L., Bonanni, P., Coppola, G., Elia, M., Mecarelli, O., Franzonı, E., Liso, P. D., et al. (2018) · Seizure · doi:10.1016/j.seizure.2018.10.016 · Cited by 83
Lorcaserin: A review of its preclinical and clinical pharmacology and therapeutic potential
Higgins, G. A., Fletcher, P. J., & Shanahan, W. R. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107417 · Cited by 80
New insights into the early mechanisms of epileptogenesis in a zebrafish model of Dravet syndrome
Tiraboschi, E., Martina, S., van der Ent, W., Grzyb, K., Gaweł, K., Cordero-Maldonado, M. L., Poovathingal, S. K., Heintz, S., Satheesh, S. V., Brattespe, J., et al. (2020) · Epilepsia · doi:10.1111/epi.16456 · Cited by 74
Precision medicine in genetic epilepsies: break of dawn?
Reif, P. S., Tsai, M., Helbig, I., Rosenow, F., & Klein, K. M. (2016) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2017.1253476 · Cited by 77
Lagae, L. G., Schoonjans, A., Gammaitoni, A. R., Galer, B. S., & Ceulemans, B. (2018) · Epilepsia · doi:10.1111/epi.14540 · Cited by 72
Self-citationSullivan, J. E., Scheffer, I. E., Lagae, L. G., Nabbout, R., Pringsheim, M., Talwar, D., Polster, T., Galer, B. S., Lock, M. D., Agarwal, A., et al. (2020) · Epilepsia · doi:10.1111/epi.16722 · Cited by 69
Self-citationAdemuwagun, I. A., Rotimi, S. O., Syrbe, S., Ajamma, Y. U., & Adebiyi, E. F. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.600050 · Cited by 68
Preventing cognitive impairment in children with epilepsy
Braun, K. P. J. (2017) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000424 · Cited by 67
Lamotrigine can be beneficial in patients with Dravet syndrome
Dalic, L., Mullen, S. A., Roulet Perez, E., & Scheffer, I. (2015) · Developmental Medicine & Child Neurology · doi:10.1111/dmcn.12593 · Cited by 64
Boyd, B., Smith, S. M., Gammaitoni, A. R., Galer, B. S., & Farfel, G. M. (2018) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cp203276 · Cited by 64
Eimon, P. M., Ghannad‐Rezaie, M., Rienzo, G. D., Allalou, A., Wu, Y., Gao, M., Roy, A., Skolnick, J., & Yanik, M. F. (2018) · Nature Communications · doi:10.1038/s41467-017-02404-4 · Cited by 65
Therapeutic advances in Dravet syndrome: a targeted literature review
Strzelczyk, A., & Schubert‐Bast, S. (2020) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2020.1801423 · Cited by 62
Fenfluramine repurposing from weight loss to epilepsy: What we do and do not know
Odi, R., Invernizzi, R. W., Gallily, T., Bialer, M., & Perucca, E. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107866 · Cited by 60
Patients with dravet syndrome in the era of stiripentol: A French cohort cross-sectional study
Liso, P. D., Chémaly, N., Laschet, J. J., Barnérias, C., Hully, M., Leunen, D., Desguerre, I., Chiron, C., Dulac, O., & Nabbout, R. (2016) · Epilepsy Research · doi:10.1016/j.eplepsyres.2016.05.012 · Cited by 59
Tupal, S., & Faingold, C. L. (2019) · Epilepsia · doi:10.1111/epi.14658 · Cited by 59
Lorcaserin therapy for severe epilepsy of childhood onset
Tolete, P., Knupp, K. G., Karlovich, M. W., DeCarlo, E., Bluvstein, J., Conway, E., Friedman, D. J., Dugan, P. C., & Devinsky, O. (2018) · Neurology · doi:10.1212/wnl.0000000000006432 · Cited by 57
Specchio, N., Pietrafusa, N., Doccini, V., Trivisano, M., Darra, F., Ragona, F., Cossu, A., Spolverato, S., Battaglia, D., Quintiliani, M., et al. (2020) · Epilepsia · doi:10.1111/epi.16690 · Cited by 56
Why we urgently need improved seizure and epilepsy therapies for children and neonates
Pressler, R., & Lagae, L. G. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107854 · Cited by 56
Self-citationEfficacy of antiepileptic drugs for the treatment of Dravet syndrome with different genotypes
Shi, X., Tomonoh, Y., Wang, W., Ishii, A., Higurashi, N., Kurahashi, H., Kaneko, S., & Hirose, S. (2015) · Brain and Development · doi:10.1016/j.braindev.2015.06.008 · Cited by 56
The challenges and innovations for therapy in children with epilepsy
Wilmshurst, J. M., Berg, A. T., Lagae, L. G., Newton, C. R. J. C., & Cross, J. H. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.58 · Cited by 55
Self-citationDravet syndrome: Advances in etiology, clinical presentation, and treatment
He, Z., Li, Y., Zhao, X., & Li, B. (2022) · Epilepsy Research · doi:10.1016/j.eplepsyres.2022.107041 · Cited by 63
From next-generation sequencing to targeted treatment of non-acquired epilepsies
Møller, R. S., Hammer, T. B., Rubboli, G., Lemke, J. R., & Johannesen, K. M. (2019) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2019.1573144 · Cited by 53
Zebrafish studies identify serotonin receptors mediating antiepileptic activity in Dravet syndrome
Griffin, A., Jaishankar, P., Grandjean, J.-M. M., Olson, S. H., Renslo, A. R., & Baraban, S. C. (2019) · Brain Communications · doi:10.1093/braincomms/fcz008 · Cited by 54
Drug Repurposing - Hypothesis, Molecular Aspects and Therapeutic Applications
Badria, F. A.-E. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.83082 · Cited by 52
Sullivan, J. E., Lagae, L. G., Cross, J. H., Devinsky, O., Guerrini, R., Knupp, K. G., Laux, L., Nikanorova, M., Polster, T., Talwar, D., et al. (2023) · Epilepsia · doi:10.1111/epi.17737 · Cited by 54
Self-citationLagae, L. G. (2020) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000902 · Cited by 56
Self-citationPersonalized medicine in genetic epilepsies – possibilities, challenges, and new frontiers
Helbig, I., & Ellis, C. A. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.107970 · Cited by 51
Rodríguez-Muñoz, M., Sánchez‐Blázquez, P., & Garzón, J. (2018) · Oncotarget · doi:10.18632/oncotarget.25169 · Cited by 49
Lai, W. W., Galer, B. S., Wong, P. C., Farfel, G. M., Pringsheim, M., Keane, M. G., & Agarwal, A. (2020) · Epilepsia · doi:10.1111/epi.16638 · Cited by 48
Landmark, C. J., Potschka, H., Auvin, S., Wilmshurst, J. M., Johannessen, S. I., Trenité, D. G. A. K.-N., & Wirrell, E. C. (2021) · Epilepsia · doi:10.1111/epi.16849 · Cited by 49
Schoonjans, A., Marchau, F., Paelinck, B. P., Lagae, L. G., Gammaitoni, A. R., Pringsheim, M., Keane, M. G., & Ceulemans, B. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1355781 · Cited by 46
Self-citationEpilepsy: key experimental therapeutics in early clinical development
Steriade, C., French, J. A., & Devinsky, O. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1743678 · Cited by 46
Galanopoulou, A. S., Löscher, W., Lubbers, L. S., O'Brien, T. J., Staley, K. J., Vezzani, A., D’Ambrosio, R., White, H. S., Sontheimer, H. W., Wolf, J. A., et al. (2021) · Epilepsia Open · doi:10.1002/epi4.12490 · Cited by 46
Fenfluramine: A Review of Pharmacology, Clinical Efficacy, and Safety in Epilepsy
Samanta, D. (2022) · Children · doi:10.3390/children9081159 · Cited by 45
SCN1B ‐linked early infantile developmental and epileptic encephalopathy
Aeby, A., Sculier, C., Bouza, A. A., Askar, B., Lederer, D., Schoonjans, A., Ghinst, M. V., Ceulemans, B., Offord, J., Lopez‐Santiago, L. F., et al. (2019) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.50921 · Cited by 44
Self-citationPernici, C. D., Mensah, J. A., Dahle, E. J., Johnson, K. J., Handy, L. J., Buxton, L., Smith, M. D., West, P. J., Metcalf, C. S., & Wilcox, K. S. (2021) · Epilepsia · doi:10.1111/epi.16925 · Cited by 41
Audit of use of stiripentol in adults with Dravet syndrome
Balestrini, S., & Sisodiya, S. M. (2016) · Acta Neurologica Scandinavica · doi:10.1111/ane.12611 · Cited by 43
Changing Landscape of Dravet Syndrome Management: An Overview
Samanta, D. (2020) · Neuropediatrics · doi:10.1055/s-0040-1701694 · Cited by 42
Strzelczyk, A., Pringsheim, M., Mayer, T., Polster, T., Klotz, K. A., Muhle, H., Alber, M., Trollmann, R., Spors, H., Kluger, G. J., et al. (2021) · Epilepsia · doi:10.1111/epi.17034 · Cited by 41
Advancing the management of childhood epilepsies
Cross, J. H., Kluger, G. J., & Lagae, L. G. (2013) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2013.02.003 · Cited by 40
Self-citationPolster, T. (2018) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2018.08.021 · Cited by 40
Fenfluramine for the Treatment of Dravet Syndrome and Lennox–Gastaut Syndrome
Balagura, G., Cacciatore, M., Grasso, E. A., Striano, P., & Verrottı, A. (2020) · CNS Drugs · doi:10.1007/s40263-020-00755-z · Cited by 40
Auvin, S., Galanopoulou, A. S., Moshé, S. L., Potschka, H., Rocha, L., Walker, M. C., & the TASK1 workgroup on drug‐resistant epilepsy of the ILAE/AES Joint Translational Task Force (2023) · Epilepsia · doi:10.1111/epi.17751 · Cited by 39
Petrucci, A. N., Joyal, K. G., Chou, J. W., Li, R., Vencer, K. M., & Buchanan, G. F. (2020) · Neuroscience · doi:10.1016/j.neuroscience.2020.11.029 · Cited by 38
Advances in the Treatment of Drug-Resistant Pediatric Epilepsy
Gonzalez‐Giraldo, E., & Sullivan, J. E. (2020) · Seminars in Neurology · doi:10.1055/s-0040-1702941 · Cited by 40
Evaluation of Selective 5-HT 2C Agonists in Acute Seizure Models
Silenieks, L. B., Carroll, N. K., Niekerk, A. V., Niekerk, E. V., Taylor, C., Upton, N., & Higgins, G. A. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00739 · Cited by 37
Epilepsy: expert opinion on emerging drugs in phase 2/3 clinical trials
Pong, A. W., Ross, J. D. C., Tyrlíková, I., Giermek, A. J., Kohli, M. P., Khan, Y. A., Salgado, R. D., & Klein, P. (2022) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2022.2059464 · Cited by 34
Zaccara, G., & Schmidt, D. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.12.011 · Cited by 33
Investigating Developmental and Epileptic Encephalopathy Using Drosophila melanogaster
Takai, A., Yamaguchi, M., Yoshida, H., & Chiyonobu, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176442 · Cited by 33
Recent Advances in Pharmacologic Treatments of Drug-Resistant Epilepsy: Breakthrough in Sight
Klein, P., Friedman, D. J., & Kwan, P. (2024) · CNS Drugs · doi:10.1007/s40263-024-01130-y · Cited by 32
Current Treatment Strategies and Future Treatment Options for Dravet Syndrome
Ziobro, J. M., Eschbach, K. L., Sullivan, J. E., & Knupp, K. G. (2018) · Current Treatment Options in Neurology · doi:10.1007/s11940-018-0537-y · Cited by 37
Serotonergic therapy in epilepsy
Gilliam, F. G., Hečimović, H., & Gentry, M. S. (2021) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000901 · Cited by 32
Fenfluramine as antiseizure medication for epilepsy
Γώγου, Μ., & Cross, J. H. (2021) · Developmental Medicine & Child Neurology · doi:10.1111/dmcn.14822 · Cited by 31
Impact of Antiseizure Medications on Appetite and Weight in Children
Buraniqi, E., Dabaja, H., & Wirrell, E. C. (2022) · Pediatric Drugs · doi:10.1007/s40272-022-00505-2 · Cited by 33
Infantile, Childhood, and Adolescent Epilepsies
Wirrell, E. C. (2016) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000000269 · Cited by 31
Assessing the role of serotonergic receptors in cannabidiol's anticonvulsant efficacy
Pelz, M. C., Schoolcraft, K. D., Larson, C. S., Spring, M. G., & López, H. H. (2017) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2017.04.045 · Cited by 31
Zebrafish Models of Epilepsy and Epileptic Seizures
Copmans, D., Siekierska, A., & de Witte, P. A. M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804066-9.00026-2 · Cited by 31
Vavers, E., Zvejniece, L., & Dambrova, M. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106771 · Cited by 30
Sills, G. J. (2023) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864231191000 · Cited by 30
Dwivedi, R., Kaushik, M., Tripathi, M., Dada, R., & Tiwari, P. (2024) · Brain Research · doi:10.1016/j.brainres.2024.149120 · Cited by 36
Cardiac adverse effects of antiseizure medications
Zaccara, G., Lattanzi, S., & Brigo, F. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2023128 · Cited by 30
Jensen, M. P., Gammaitoni, A. R., Galer, B. S., Salem, R., Wilkie, D., & Amtmann, D. (2022) · Epilepsy Research · doi:10.1016/j.eplepsyres.2022.106976 · Cited by 29
Metadata
- Authors
- Ceulemans, B., Boel, M., Leyssens, K., Van Rossem, C., Neels, P., Jorens, P. G., & Lagae, L.
- Affiliations
- University of Antwerp (BE)
- KU Leuven (BE)
- Corresponding author
- Ceulemans, Berten
- Venue
- Epilepsia
- Publisher
- Wiley
- Published
- 2012-05-03
- Volume
- 53
- Issue
- 7
- Pages
- 1131-1139
- ISSN
- 0013-9580 (ISSN-L)
- 1528-1167
- OpenAlex
- W1926532831
- Cited by
- 210
- References
- 51
- Citations by year
- 2026: 7 · 2025: 10 · 2024: 18 · 2023: 13 · 2022: 20 · 2021: 28 · 2020: 27 · 2019: 23 · 2018: 18 · 2017: 13 · 2016: 15 · 2015: 8 · 2014: 5 · 2013: 3 · 2012: 1
- FWCI
- 3.88
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Epilepsia (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmacological Effects and Toxicity Studies
- Health Sciences › Medicine › Physiology (medical) › Diet and metabolism studies
- Keywords
- Dravet syndrome, fenfluramine, adjunctive therapy, seizure freedom, drug repurposing, amphetamine-type stimulants, pulmonary hypertension, drug withdrawal, seizure recurrence, long-term follow-up
- MeSH terms
- Adolescent, Adult, Anticonvulsants, Child, Preschool, Electroencephalography, Epilepsies, Myoclonic, Female, Fenfluramine, Follow-Up Studies, Humans, Male, Selective Serotonin Reuptake Inhibitors, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
